Literature DB >> 25400369

18 Fluoride-fluorodeoxyglucose positron emission tomography in initial staging and response assessment of primary non-Hodgkin lymphoma of the tibia.

Chidambaram Natrajan Balasubramanian Harisankar1, Jijoe John2, Thattaamuriyil Padmakumari Lekshmi2, Arun Warrier3.   

Abstract

Primary lymphoma of the bone is a rare clinical presentation constituting to <1% of all lymphomas. The long bones are usually involved. Combined treatment with chemotherapy and radiation offers long-term survival. The authors present the role of 18 fluoride-fluorodeoxyglucose positron emission tomography-computerized tomography in initial staging and response assessment in a case of primary diffuse large B cell lymphoma of the tibia.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; fludeoxyglucose positron emission tomography; primary bone lymphoma; response assessment

Year:  2014        PMID: 25400369      PMCID: PMC4228593          DOI: 10.4103/0972-3919.142636

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


INTRODUCTION

Primary bone lymphoma is a rare, but distinct clinical entity. Both Hodgkin and non-Hodgkin lymphoma (NHL) can involve the bones. The involvement may be solitary or multi-focal. Patients with primary bone lymphoma usually have a good prognosis. Combined treatment with chemotherapy and radiation has good response with the majority of the low-risk patients surviving until 10 years. We present the role of 18 fluoride-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (18F-FDG PET-CT) in an interesting case of primary diffuse large B cell lymphoma (DLBCL) of the tibia.

CASE REPORT

A 53-year-old-male patient who presented with pain and swelling of the right lower limb was evaluated. A biopsy from the swelling revealed DLBCL. He was referred to our center for a whole body 18F-FDG PET-CT for initial staging. Pretreatment 18F-FDG PET-CT of the thigh and leg showed intense metabolic activity in a large soft tissue mass arising from the proximal part of right tibia [Figure 1]. No abnormal metabolic activity was noted in the rest of the body.
Figure 1

Pretreatment 18 fluoride-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) showing intense metabolically active soft tissue lesion noted involving the proximal part of right tibia (coronal PET (a), fused coronal PET CT (b), sagittal PET (d), sagittal fused PET CT (e) and maximum intensity projection (MIP) lower limbs (f)). MIP of the whole body FDG PET (c) showing no abnormal lymph nodes elsewhere in the body

Pretreatment 18 fluoride-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) showing intense metabolically active soft tissue lesion noted involving the proximal part of right tibia (coronal PET (a), fused coronal PET CT (b), sagittal PET (d), sagittal fused PET CT (e) and maximum intensity projection (MIP) lower limbs (f)). MIP of the whole body FDG PET (c) showing no abnormal lymph nodes elsewhere in the body The patient underwent chemotherapy and local radiation to the involved site and was referred for an 18F-FDG PET-CT 3 months after the completion of treatment. Posttreatment 18F-FDG PET-CT was normal with complete regression of previously noted abnormality [Figure 2].
Figure 2

Posttreatment 18 fluoride-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) showing complete resolution of metabolic activity in the proximal part of right tibia (coronal PET (a), fused coronal PET CT (b), sagittal PET (d), sagittal fused PET CT (e) and maximum intensity projection (MIP) lower limbs (f)). MIP of the whole body FDG PET (c) showing no abnormal lymph nodes elsewhere in the body. Minimal diffuse FDG uptake in the lower limbs muscles is likely related to local radiotherapy

Posttreatment 18 fluoride-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) showing complete resolution of metabolic activity in the proximal part of right tibia (coronal PET (a), fused coronal PET CT (b), sagittal PET (d), sagittal fused PET CT (e) and maximum intensity projection (MIP) lower limbs (f)). MIP of the whole body FDG PET (c) showing no abnormal lymph nodes elsewhere in the body. Minimal diffuse FDG uptake in the lower limbs muscles is likely related to local radiotherapy

DISCUSSION

Extra nodal lymphomas are fairly common. Primary bone lymphomas represent approximately 5% of the extranodal lymphomas, majority of which are DLBCL.[1] Primary bone lymphomas constitute to <1% of all NHL.[2] Primary Hodgkin lymphoma of the bone is extremely rare.[3] Most patients present with localized pain, swelling or pathological fracture. They can arise from any bone, but long bones (femurs and tibiae) are the common sites. 18F-FDG PET CT helps in identification of lymph nodal involvement and also differentiation of monostotic from polyostotic involvement by lymphoma. 18F-FDG PET-CT is beneficial in the response assessment and effectiveness of treatment. Viable tumor lesions are difficult to be differentiate from bone fibrosis and remodeling using conventional modalities. 18F-FDG PET is also more sensitive than magnetic resonance imaging in identifying response.[4] Primary lymphoma involving the bone usually has an excellent prognosis.[5] Patients treated with combined modality versus single modality therapy were found to have a superior outcome, with a significantly better survival. The 5-year overall survival for patients treated with combined modality was 95% in one of the largest studies.[5] Reports on the utility of 18F-FDG PET-CT in primary bone lymphomas have also been published.[67] Role of 18F-FDG PET-CT in initial staging and response assessment in lymphomas has been well-established.[89] This case reports adds to the existing knowledge that 18F-FDG PET-CT is a useful modality in assessment of primary bone lymphoma.
  9 in total

Review 1.  Primary bone lymphoma.

Authors:  N G Mikhaeel
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-03-06       Impact factor: 4.126

2.  Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone.

Authors:  Y H Park; S Kim; S-J Choi; B-Y Ryoo; S H Yang; G J Cheon; C-W Choi; S M Lim; J Y Yoo; S-S Lee
Journal:  Ann Oncol       Date:  2005-05-03       Impact factor: 32.976

3.  Interesting image. FDG-PET/CT in primary large B-cell lymphoma of the hard palate.

Authors:  Dimitrios Kalkanis; Maria Kalkani; Hilton Gomes; Fabio Paes; Panagiotis Sideras; George N Sfakianakis
Journal:  Clin Nucl Med       Date:  2010-01       Impact factor: 7.794

4.  Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.

Authors:  Kathryn Beal; Laura Allen; Joachim Yahalom
Journal:  Cancer       Date:  2006-06-15       Impact factor: 6.860

Review 5.  PET/CT for therapy response assessment in lymphoma.

Authors:  Martin Hutchings; Sally F Barrington
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 6.  [Primary multifocal osseous Hodgkin lymphoma].

Authors:  Gaku Oshikawa; Ayako Arai; Koji Sasaki; Ryo Ichinohasama; Osamu Miura
Journal:  Rinsho Ketsueki       Date:  2009-02

Review 7.  Primary lymphomas of bone.

Authors:  Panagiotis Kitsoulis; Marianna Vlychou; Alexandra Papoudou-Bai; Georgios Karatzias; Antonia Charchanti; Niki John Agnantis; Maria Bai
Journal:  Anticancer Res       Date:  2006 Jan-Feb       Impact factor: 2.480

Review 8.  FDG-PET/CT based response-adapted treatment.

Authors:  Lioe-Fee de Geus-Oei; Dennis Vriens; Anne I J Arens; Martin Hutchings; Wim J G Oyen
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

9.  Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.

Authors:  Joaquim Bosch-Barrera; Leire Arbea; Maria J García-Velloso; Ignacio Gil-Bazo; Jesús García-Foncillas; Carlos Panizo
Journal:  Cases J       Date:  2009-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.